Oncogene-induced senescence occurs following oncogene activation in normal cells and is considered as a critical tumor-suppressing mechanism. Ubiquitin-specific protease 10 (USP10) has been reported to play a vital role in oncogene-induced senescence via the deubiquitination-dependent stabilization of p14ARF. However, knowledge of the clinical significance of USP10 and p14ARF expression in patients with small intestinal adenocarcinoma is limited. To study the clinical significance of USP10 and p14ARF expression, we performed immunohistochemistry for USP10 and p14ARF on 195 surgically resected small intestinal adenocarcinoma specimens. Furthermore, we performed methylation analysis on five small intestinal adenocarcinoma samples and matched adjacent normal intestinal tissue samples. UPS10 (p = 0.023) and p14ARF (p = 0.007) expression were significantly decreased in adenocarcinoma in comparison with normal tissue. The loss of USP10 was observed in 124/194 (63.9%) of small intestinal adenocarcinoma samples and was correlated with a higher pT stage (p = 0.044), lymphatic invasion (p = 0.033), and the absence of sporadic adenoma (p = 0.024) and peritumoral dysplasia (p = 0.019). p14ARF expression was downregulated in 75/195 (38.5%) of small intestinal adenocarcinoma samples and was associated with vascular (p = 0.011) and lymphatic (p = 0.013) invasions. The loss of USP10 expression was associated with the loss of p14ARF expression (r = 0.342, p \ 0.001). Multivariate survival analysis revealed that the combined loss of USP10 and p14ARF expression could be an independent prognostic factor for overall survival in small intestinal adenocarcinoma. Furthermore, the aberrant hypermethylation of the USP10 and p14ARF promoter could be a key mechanism for the downregulation of USP10 and p14ARF proteins in small intestinal adenocarcinoma. These findings suggest that the dual loss of USP10 and p14ARF could be used as a prognostic indicator of small intestinal adenocarcinoma.
Introduction
Small intestinal adenocarcinoma is a rare tumor and accounts for only 2% of gastrointestinal tract malignancies. 1 There were 10,190 estimated new cases of small intestinal adenocarcinoma in 2017 in the United States. 2 The diagnosis of small intestinal adenocarcinoma can be challenging due to the lack of effective diagnostic tools and non-specific clinical symptoms at advanced stages. 1, 3 This can negatively affect the survival rate; small intestinal adenocarcinoma remains a global public health problem with a 5-year overall survival rate of 14%-45%. 4 Oncogene-induced senescence, a permanent type of growth arrest, plays a protective role against oncogenic stress-mediated transformation, and it is a mechanism of natural tumor suppression. 5 This has led to increased interest in pathways that mediate oncogene-induced senescence. Oncogene-induced senescence is independent of telomere shortening 6 and requires the involvement of the p19 ARF -p53 and p16
INK4A
-RB tumor-suppressor pathways. [7] [8] [9] [10] Given that oncogene-induced senescence is composed of multiple mechanisms in response to oncogene activation, the molecular mechanism of oncogeneinduced senescence remains unclear. Accordingly, the assessment of oncogene-induced senescence-related proteins in clinical tumor samples will contribute to the understanding of the molecular mechanism of oncogeneinduced senescence, and this knowledge could potentially lead to the development of better therapeutic approaches and increased survival of patients.
Ubiquitin-specific protease 10 (USP10) is a member of the ubiquitin-specific protease (USP) family, which specifically cleaves ubiquitin from ubiquitin-conjugated protein substrates, and its related pathways are known to be involved in apoptosis, autophagy, and DNA damage. 11, 12 Recently, USP10 has been reported to be a novel regulator of p53, providing an alternative mechanism of inhibiting p53 in cancers with wild-type p53. 13 In addition, either the overexpression or decreased expression of USP10 has been associated with poor prognosis in different tumor types including stomach cancer, breast cancer, and glioblastoma. [14] [15] [16] p14ARF is encoded by an alternative reading frame within the INK4a/ARF locus at chromosome 9p21, which also encodes the p16 protein.
17 p14ARF increases TP53 stability by antagonizing the MDM2-mediated degradation of TP53, thereby facilitating p53-mediated cell cycle arrest and apoptosis; 18 either promoter hypermethylation or loss could be the mechanism of p14ARF inactivation. The majority of previous studies on p14ARF have focused on genetic aberrations (especially promoter hypermethylation) rather than alterations in protein expression. 19, 20 A few studies have reported the downregulation of p14ARF in various human cancers including gastric, breast, and lung cancers. [21] [22] [23] Recently, Ko et al. 24 reported that USP10 could promote a fail-safe program to prevent hyperproliferation via the stabilization of p14ARF in non-small cell lung cancer. The accumulated evidence suggests that the altered expression of USP10 and/or p14ARF may be linked to tumorigenesis. Nevertheless, knowledge of the clinical and prognostic significance of USP10 and p14ARF expression in patients with small intestinal adenocarcinoma is limited.
In this study, we assessed the prognostic significance of USP10 and p14ARF in formalin-fixed paraffinembedded (FFPE) small intestinal adenocarcinoma specimens by immunohistochemistry and quantitative image analysis. In addition, we investigated the potential association between the loss of USP10 and p14ARF protein expression and methylation.
Materials and methods

Patients and tumor specimens
A total of 195 cases of surgically resected small intestinal adenocarcinoma were retrieved from 22 South Korean hospitals and institutions by the Korean Small Intestinal Cancer Study Group, as previously reported. 1 All procedures were conducted in accordance with the Declaration of Helsinki. Tissue samples were collected from patients who signed the written informed consent form, which was approved by the Regional Institutional Review Board of Asan Medical Center (approval no. S2016-1710-0001). The tumors included primary carcinomas in the duodenum, jejunum, and ileum but excluded carcinomas arising from other gastrointestinal tract sites and the ampulla of Vater, pancreas, cecum, and appendix. Similar to a previous study, 1 clinical and pathological information was recorded, including location, size, histological subtype, differentiation, growth pattern, primary tumor (pT) category, retroperitoneal seeding, other intestinal loop invasions, metastasis to lymph node, and presence of perineural and lymphovascular invasion.
Tissue microarray and immunohistochemistry
Tissue microarray cores were constructed from archival FFPE tissue blocks as previously described. 25 Immunohistochemically stained slides were scanned by NanoZoomer 2.0 HT (Hamamatsu Photonics K.K., Hamamatsu, Japan) at 3 20 objective magnification (0.5 mm resolution). The captured images were analyzed using Visiopharm software version 4.5.1.324 (Visiopharm, Hørsholm, Denmark). A brown staining intensity (0 = negative, 1 = weak, 2 = moderate, and 3 = strong) was obtained using a predefined algorithm and optimized settings. 27, 28 The overall immunohistochemical score (histoscore) was expressed as the percentage of positive cells multiplied by their staining intensity (possible range: 0-300).
DNA methylation analysis
Genomic DNA was isolated from five normal tissue samples and five primary small intestinal adenocarcinoma samples using a standard phenol-chloroform method. The DNA (2 mg) was modified with bisulfite using the EZ DNA Methylation Kitä (Zymo Research, Orange, CA, USA). Methylation analysis of gene promoters was performed using methylationspecific PCR (MSP) primer pairs located close to the putative transcription start site in the 5# CpG island with 2 mL of bisulfite-treated DNA as the template and JumpStart REDTaq DNA Polymerase (SigmaAldrich, St. Louis, MO, USA) for amplification as previously described. 29 p14ARF/CDKN2A primers were used for bisulfite sequencing, 30 and the primer sequences designed for USP10 were within the 1 kb upstream region of the CpG islands. The primer sequences of USP10 for the reaction were 5#-TTT AGGTAGGATTTGGGGAGTG-3# (sense) and 5#-AAAAACAAACAAATAAAAATAACAAC-3# (antisense), which amplified a 262-bp product. For bisulfite sequence analysis, PCR amplicons were separated by 2% agarose gel electrophoresis, purified with the Gel Extraction Kit (Qiagen GmbH, Hilden, Germany), and cloned using the TOPO TA vector system (Invitrogen, Carlsbad, CA, USA). Individual clones were isolated and purified using the NucleoSpin Plasmid Isolation Kit (Macherey-Nagel, Du¨ren, Germany). Randomly selected positive clones (10-15 from each sample) were sequenced using the M13F primer, and the methylation status of each CpG dinucleotide was analyzed.
Statistical analysis
The association between protein expression and clinicopathological characteristics was determined using the chi-square test. For survival analysis, expression values were dichotomized (positive vs negative) with the cutoff values showing the most discriminative power (histoscore of 237 for USP10 and 129 for p14ARF). Overall survival according to protein expression was analyzed using the Kaplan-Meier method, and the survival curves were compared with the log-rank test. Subsequently, a Cox multivariate proportional hazards model was used for analysis and adjusted for the following clinical/pathological variables: histologic subtype, pT category, lymph node metastasis, other loop invasions, retroperitoneal seeding, perineural and lymphovascular invasions, sporadic adenoma, and peritumoral dysplasia. Statistical analysis was performed using SPSS version 21.0 (SPSS, Chicago, IL, USA) and R statistical package (version 3.1.2).
Results
Expression of USP10 and p14ARF proteins
Normal epithelial cells in the crypts of the small intestine and epithelial plasma cells were stained by USP10 as a diffuse cytoplasmic pattern. The cytoplasm and nucleus were stained by p14ARF in the normal small intestinal mucosa with an apicoluminal pattern ( Figure  1 , left column), whereas the tumor cells were stained with diffuse cytoplasmic and nuclear patterns ( Figure  1 , middle and right columns). Although the TMA contains 195 cases of small intestinal adenocarcinoma and matched normal, 194 out of 195 cases were found suitable for USP10 evaluation due to the complexity of sectioning and heterogeneity. In total, 70 (36.1%) patients showed immunoreactivity for USP10, and 124 (63.9%) patients showed loss of immunoreactivity for USP10. In addition, 120 (61.5%) patients were immunopositive for p14ARF, and 75 (38.5%) patients showed loss of immunoreactivity for p14ARF. USP10 expression status was positively correlated with p14ARF expression status (Spearman's rho = 0.342, p \ 0.001; Figure 2 (a)).
In cases with loss of USP10 expression, there was also a loss of p14ARF immunolabeling. Furthermore, there was a significant positive correlation between USP10 
Clinical and pathological characteristics according to USP10 and p14ARF expression
The USP10 and p14ARF expression in small intestinal adenocarcinoma were significantly lower than that in corresponding adjacent normal tissue (p = 0.023 and p = 0.007, respectively) ( Figure 3(a) ). In addition, the combined expression of USP10 high /p14ARF
high was positively associated with normal tissue (Figure 3(b) ). The loss of USP10 was correlated with male predominance (p = 0.014), a higher pT category (p = 0.044), the presence of lymphatic invasion (p = 0.033), and the absence of sporadic adenoma (p = 0.024) and peritumoral dysplasia (p = 0.019). In addition, the loss of p14ARF was correlated with the presence of vascular (p = 0.011) and lymphatic (p = 0.013) invasions. Other clinicopathological parameters were not correlated with the loss of USP10 and/or p14ARF expression ( Table 1) . The combined expression of USP10 high /p14ARF
high was negatively associated with vascular (p = 0.037) and Other parameters including a higher pathological T stage (p = 0.020), the presence of lymph node metastasis (p \ 0.001), perineural invasion (p \ 0.001), vascular invasion (p = 0.010), lymphatic invasion (p \ 0.001), other loop invasions (p = 0.036), and retroperitoneal seeding (p \ 0.001) were associated with a shorter overall median survival time (Table 2) .
Multivariate analysis revealed that the loss of USP10 expression was an independent poor prognostic factor (HR = 3.04, 95% CI = 1.79-5.18, p \ 0.001), and both the loss of USP10 and p14ARF expression showed a similar result (HR = 3.76, 95% CI = 1.93-7.23, p \ 0.001). However, the loss of p14ARF was not an independent prognostic factor (p = 0.587). Analysis of the expression of both USP10 and p14ARF revealed that the dual loss of USP10 and p14ARF expression was an independent poor prognostic factor (HR = 3.73, 95% CI = 1.93-7.32, p \ 0.001). In addition, lymph node metastasis (p = 0.044), retroperitoneal seeding (p = 0.003), and lymphatic invasion (p = 0.018) were independent poor prognostic factors (Table 3) .
Regulation of USP10 and p14ARF downregulation by promoter hypermethylation
Gene silencing is known to be associated with promoter DNA hypermethylation in human cancers. 31 In addition, p14ARF gene silencing has been reported to be regulated by promoter hypermethylation in several cancer types. [32] [33] [34] Nevertheless, the methylation level of USP10 in human cancers has not been actively investigated. Therefore, the level of p14ARF and USP10 promoter methylation in normal tissues and small intestinal adenocarcinoma cancer tissues was examined by bisulfite sequencing analysis. The promoter region of the p14ARF gene showed dense hypermethylation in small intestinal adenocarcinoma tissues (70%-87% of total CpG sites) compared with normal tissues (5.3%-9% of total CpG sites) ( Figure 5 ). The USP10 gene showed dense hypermethylation in small intestinal adenocarcinoma tissues (40%-59% of total CpG sites), and this hypermethylation was also detected in normal tissues (26%-52% of total CpG sites). These findings indicated that the downregulation of p14ARF and USP10 expression was regulated by promoter DNA hypermethylation; however, p14ARF showed cancerspecific hypermethylation.
Discussion
Due to the rarity of small intestinal adenocarcinoma, there is a lack of sufficient data to adequately characterize the patient population. Moreover, the immunophenotyping and molecular markers that can aid early detection and treatment are limited. Therefore, there is a great need to identify potential molecular markers that will provide prognostic and predictive value for small intestinal adenocarcinoma. In this study, we demonstrated an association between USP10 and p14ARF protein expression and their combined potential as a prognostic marker for small intestinal adenocarcinoma. We also showed that the downregulation of USP10 and p14ARF expression may be associated with promoter hypermethylation.
Two different modes of cellular senescence have been considered. Replicative senescence is observed in aged cells and attributed to short telomeres typically following excessive cell divisions. Oncogene-induced senescence is triggered by oncogenes, resulting in premature senescence or the apoptosis of cells exposed to oncogenic stress including genotoxic and oxidative stress. 24 Both replicative senescence and oncogene-induced senescence share many common changes in gene expression; nevertheless, differences in triggers and effectors have also been characterized. 35 The DNA methylation of promoter CpG islands is strongly associated with specific genes that play a role in the initiation and establishment of senescence. 36 Grasso et al. 37 reported that Nurpr1, a chromatin protein, modified the effects of Kras G12D -induced senescence by regulating Dnmt1 expression and consequently genomic-wide levels of DNA methylation. Promoter methylation is one of the key epigenetic mechanisms that regulate gene expression, and the aberrant DNA hypermethylation of gene promoter regions is an important inactivation mechanism for silencing tumor-suppressor genes in most cancers. 38 Various studies have found that p14ARF is frequently inactivated by promoter hypermethylation in different human cancers. 39 In addition, the silencing of p14ARF has been linked to altered histone acetylation in melanoma. 40 In this study, we report for the first time that the downregulation of USP10 may be associated with promoter hypermethylation in small intestinal adenocarcinoma.
USPs play important roles in many cellular processes such as the cell cycle, signal transduction, and transcriptional activation, and several USPs have been implicated in human tumorigenesis.
41 USP10 (a member of the USP family) deubiquitinates p53 and MDM2 (a known regulator of cellular p53) are involved in the reverse translocation and degradation of p53. 13 Previous studies have shown that USP10 can suppress tumor formation by enhancing p53 stability. 12, 13 Recently, Sun et al. 42 suggest that USP10 acts as a tumor suppressor in lung cancer cells by deubiquitinating and stabilizing PTEN. The loss of USP10 expression has been observed in several types of cancers including renal cell, 13 gastric, 14 lung, 42 and pancreatic cancers. 43 In particular, the decreased expression of USP10 has been reported to correlate with poor prognosis in gastric cancer.
14 Conversely, USP10 overexpression has been reported in breast cancer 16 and glioblastoma, 15 and it may be associated with poor outcomes in glioblastoma 15 and prostate cancer. 44 Yuan et al. 13 demonstrated that USP10 overexpression could suppress the growth of tumor cells with wild-type TP53; however, USP10 could act as an oncogenic protein in renal carcinoma cells with mutant TP53. Although we did not examine TP53 mutation in this study, the mutation rate of TP53 or p53 protein overexpression in small intestinal adenocarcinoma has been reported to range from 24% to 52%. 45 These previous findings suggest that USP10 may act as a tumor suppressor or oncogenic protein depending on tumor cell conditions including gene mutations. A recent study also showed that USP7 can act as an oncogene or tumor-suppressor gene depending on the context. 46 In this study, we observed that the loss of USP10 expression was more frequent in advanced stage tumors compared with early-stage tumors ( Table 1 ). The loss of USP10 expression was a poor prognostic factor with respect to the overall survival according to Cox's proportional hazards model (Table 3) . Our results suggest that USP10 has a tumor suppressive effect in small intestinal adenocarcinoma and could be a novel prognostic marker for patients with small intestinal adenocarcinoma. Nevertheless, further studies are needed to elucidate the underlying molecular mechanism of USP10 in small intestinal adenocarcinoma. p14ARF/CDKN2A is well known as a tumorsuppressor protein and an important mediator of oncogenic p53 activation. p14ARF binds to MDM2 and stabilizes p53 in response to DNA damage or cellular stress. 47, 48 The transcriptional silencing of the p14ARF/ CDKN2A gene through DNA promoter hypermethylation is associated with carcinogenesis in many tumors. Interestingly, a study reported that p14ARF/CDKN2A promoter hypermethylation was only detected in 5 of 56 (8.9%) small intestinal adenocarcinoma samples. 49 In this study, the loss of p14ARF protein expression was observed in 38.5% (75 of 195) of the samples. These results suggest that the hypermethylation of p14ARF is not a common event in small intestinal adenocarcinoma, and there might be different mechanisms involved in the inactivation of p14ARF. Recently, Ko et al. 24 demonstrated that c-Myc could induce p14ARF protein stabilization by activating USP10 transcription. USP10 ablation prevents c-Myc-induced cellular senescence by destabilizing p14ARF. Clinically, the downregulation of USP10 and p14ARF protein expression has been detected in non-small cell lung cancer, and the loss of USP10 and p14ARF protein expression has been reported to correlate with poor prognosis in non-small cell lung cancer. 24 These findings suggest that disrupting the transcriptional effect of c-Myc on USP10 would likely contribute to the suppression of oncogeneinduced senescence, and the c-Myc/USP10/p14ARF axis could be involved in the tumorigenesis of non-small cell lung cancer. Consistent with previous studies, we found that the loss of USP10 expression was frequently detected in advanced-stage tumors (Table 1) , and there was a significant positive correlation between USP10 and p14ARF expression (Figure 2 and Supplementary Figure S1 ). Patients with the loss of USP10, loss of p14ARF, and dual loss of USP10 and p14ARF expression had a significantly worse overall survival compared to those with intact USP10, intact p14ARF, and intact USP10 and p14ARF expression (Figure 4) . Notably, the loss of USP10 and dual loss of USP10 and p14ARF expression were poor prognostic factors for small intestinal adenocarcinoma (Table 3) . Overall, the results strongly support our hypothesis that the c-Myc/USP10/ p14ARF axis may be disrupted in small intestinal adenocarcinoma and may contribute to the bypass of oncogene-induced senescence in human cancers.
In summary, we demonstrated that the loss of USP10 expression was associated with advanced tumor phenotypes, and the dual loss of USP10 and p14ARF could be a poor prognostic factor for overall survival in small intestinal adenocarcinoma. Furthermore, the loss of USP10 and p14ARF expression may be regulated by promoter hypermethylation in small intestinal adenocarcinoma. In addition, the p14ARF-USP10 axis may play a role in cancer progression. USP10 and p14ARF protein expression could potentially serve as a novel prognostic indicator for predicting survival time in small intestinal adenocarcinoma, which may be helpful in the management of patients with small intestinal adenocarcinoma. Further elucidation of the underlying molecular mechanism of the USP10-p14ARF axis will contribute to the development of novel therapies for small intestinal adenocarcinoma.
